BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 31302389)

  • 1. Effectiveness and safety of surgical glove compression therapy as a prophylactic method against nanoparticle albumin-bound-paclitaxel-induced peripheral neuropathy.
    Tsuyuki S; Yamagami K; Yoshibayashi H; Sugie T; Mizuno Y; Tanaka S; Kato H; Okuno T; Ogura N; Yamashiro H; Takuwa H; Kikawa Y; Hashimoto T; Kato T; Takahara S; Katayama T; Yamauchi A; Inamoto T
    Breast; 2019 Oct; 47():22-27. PubMed ID: 31302389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the efficacy of cryotherapy and compression therapy for preventing nanoparticle albumin-bound paclitaxel-induced peripheral neuropathy: A prospective self-controlled trial.
    Kanbayashi Y; Sakaguchi K; Ishikawa T; Ouchi Y; Nakatsukasa K; Tabuchi Y; Kanehisa F; Hiramatsu M; Takagi R; Yokota I; Katoh N; Taguchi T
    Breast; 2020 Feb; 49():219-224. PubMed ID: 31901783
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the effect of compression therapy using surgical gloves on nanoparticle albumin-bound paclitaxel-induced peripheral neuropathy: a phase II multicenter study by the Kamigata Breast Cancer Study Group.
    Tsuyuki S; Senda N; Kanng Y; Yamaguchi A; Yoshibayashi H; Kikawa Y; Katakami N; Kato H; Hashimoto T; Okuno T; Yamauchi A; Inamoto T
    Breast Cancer Res Treat; 2016 Nov; 160(1):61-67. PubMed ID: 27620884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Compression therapy using surgical gloves does not prevent paclitaxel-induced peripheral neuropathy: results from a double-blind phase 2 trial.
    Kotani H; Terada M; Mori M; Horisawa N; Sugino K; Kataoka A; Adachi Y; Gondou N; Yoshimura A; Hattori M; Sawaki M; Takahata C; Kobara M; Iwata H
    BMC Cancer; 2021 May; 21(1):548. PubMed ID: 33985457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Possibility of Prolonging Treatment by Preventing Paclitaxel-Induced Peripheral Neuropathy Using Compression Therapy].
    Tsuyuki S; Hamada-Nishimoto M; Kang Y; Katayama T
    Gan To Kagaku Ryoho; 2022 Nov; 49(11):1241-1245. PubMed ID: 36412028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized controlled trial using surgical gloves to prevent chemotherapy-induced peripheral neuropathy by paclitaxel in breast cancer patients (AIUR trial).
    Kang YJ; Yoon CI; Yang YJ; Baek JM; Kim YS; Jeon YW; Rhu J; Yi JP; Kim D; Oh SJ
    BMC Cancer; 2023 Jun; 23(1):570. PubMed ID: 37340369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of the development of nab-paclitaxel-induced peripheral neuropathy in breast cancer patients: post hoc analysis of a prospective, phase II, self-controlled clinical trial.
    Kanbayashi Y; Sakaguchi K; Ishikawa T; Tabuchi Y; Takagi R; Yokota I; Katoh N; Takayama K; Taguchi T
    Med Oncol; 2022 Jul; 39(10):153. PubMed ID: 35852641
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of peripheral neuropathy induced by nab-paclitaxel treatment for breast cancer.
    Ohno T; Mine T; Yoshioka H; Kosaka M; Matsuda S; De Kerckhove M; De Kerckhove C; Irie J; Inoue K; Haraguchi M; Kitajima M; Shinichiro I; Tokai H; Tanaka T; Izumida R
    Anticancer Res; 2014 Aug; 34(8):4213-6. PubMed ID: 25075049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II trial of dose-reduced nab-paclitaxel for patients with previously treated, advanced or recurrent gastric cancer (OGSG 1302).
    Tamura S; Taniguchi H; Nishikawa K; Imamura H; Fujita J; Takeno A; Matsuyama J; Kimura Y; Kawada J; Hirao M; Hirota M; Fujitani K; Kurokawa Y; Sakai D; Kawakami H; Shimokawa T; Satoh T
    Int J Clin Oncol; 2020 Dec; 25(12):2035-2043. PubMed ID: 32926227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial.
    Untch M; Jackisch C; Schneeweiss A; Conrad B; Aktas B; Denkert C; Eidtmann H; Wiebringhaus H; Kümmel S; Hilfrich J; Warm M; Paepke S; Just M; Hanusch C; Hackmann J; Blohmer JU; Clemens M; Darb-Esfahani S; Schmitt WD; Dan Costa S; Gerber B; Engels K; Nekljudova V; Loibl S; von Minckwitz G; ;
    Lancet Oncol; 2016 Mar; 17(3):345-356. PubMed ID: 26869049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II, multicenter, single-arm study of tri-weekly low-dose nanoparticle albumin-bound paclitaxel chemotherapy for patients with metastatic or recurrent breast cancer.
    Yamamoto S; Maeda N; Nagashima Y; Kubo H; Sato Y; Matsui H; Inoue Y; Shindo Y; Kanekiyo S; Sakamoto K; Suzuki N; Takeda S; Ueno T; Yoshino S; Hazama S; Oka M; Nagano H
    Breast Cancer; 2017 Nov; 24(6):783-789. PubMed ID: 28439763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and Tolerability of Nab-paclitaxel in Younger versus Elderly Patients With Metastatic HR-positive/HER2-negative Breast Cancer: Results From the Noninterventional, Prospective Study NABUCCO.
    Potthoff K; Stötzer O; Söling U; Hansen R; Harde J; Dille S; Nusch A; Marschner N
    Clin Breast Cancer; 2020 Jun; 20(3):e315-e326. PubMed ID: 32273207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and Efficacy of Low-dose Nanoparticle Albumin-bound Paclitaxel for HER2-negative Metastatic Breast Cancer.
    Takashima T; Kawajiri H; Nishimori T; Tei S; Nishimura S; Yamagata S; Tokunaga S; Mizuyama Y; Sunami T; Tezuka K; Ikeda K; Ogawa Y; Kashiwagi S; Noda S; Onoda N; Ishikawa T; Kudoh S; Takada M; Hirakawa K; Ohira M
    Anticancer Res; 2018 Jan; 38(1):379-383. PubMed ID: 29277798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prospective comparison study utilizing patient-reported outcomes of taxane-related peripheral neuropathy between nab-paclitaxel and standard paclitaxel in patients with breast cancer.
    Kida K; Yamada A; Shimada K; Narui K; Sugae S; Shimizu D; Doi T; Oba M; Endo I; Ishikawa T
    Breast Cancer; 2024 May; 31(3):409-416. PubMed ID: 38453739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Pilot, Phase II, Randomized, Open-Label Clinical Trial Comparing the Neurotoxicity of Three Dose Regimens of Nab-Paclitaxel to That of Solvent-Based Paclitaxel as the First-Line Treatment for Patients with Human Epidermal Growth Factor Receptor Type 2-Negative Metastatic Breast Cancer.
    Ciruelos E; Apellániz-Ruiz M; Cantos B; Martinez-Jáñez N; Bueno-Muiño C; Echarri MJ; Enrech S; Guerra JA; Manso L; Pascual T; Dominguez C; Gonzalo JF; Sanz JL; Rodriguez-Antona C; Sepúlveda JM
    Oncologist; 2019 Nov; 24(11):e1024-e1033. PubMed ID: 31023863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the effect of N-acetylcysteine on the prevention and amelioration of paclitaxel-induced peripheral neuropathy in breast cancer patients: a randomized controlled study.
    Khalefa HG; Shawki MA; Aboelhassan R; El Wakeel LM
    Breast Cancer Res Treat; 2020 Aug; 183(1):117-125. PubMed ID: 32601973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase IIA trial of acupuncture to reduce chemotherapy-induced peripheral neuropathy severity during neoadjuvant or adjuvant weekly paclitaxel chemotherapy in breast cancer patients.
    Bao T; Seidman AD; Piulson L; Vertosick E; Chen X; Vickers AJ; Blinder VS; Zhi WI; Li Q; Vahdat LT; Dickler MN; Robson ME; Mao JJ
    Eur J Cancer; 2018 Sep; 101():12-19. PubMed ID: 30007894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Weekly paclitaxel plus ramucirumab versus weekly nab-paclitaxel plus ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy-the P-SELECT trial (WJOG10617G)-a randomised phase II trial by the West Japan Oncology Group.
    Hirata K; Hamamoto Y; Ando M; Imamura CK; Yoshimura K; Yamazaki K; Hironaka S; Muro K
    BMC Cancer; 2020 Jun; 20(1):548. PubMed ID: 32532230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant triweekly nanoparticle albumin-bound paclitaxel followed by epirubicin and cyclophosphamide for Stage II/III HER2-negative breast cancer: evaluation of efficacy and safety.
    Shimada H; Ueda S; Saeki T; Shigekawa T; Takeuchi H; Hirokawa E; Sugitani I; Sugiyama M; Takahashi T; Matsuura K; Yamane T; Kuji I; Hasebe T; Osaki A
    Jpn J Clin Oncol; 2015 Jul; 45(7):642-9. PubMed ID: 25989989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial.
    Shitara K; Takashima A; Fujitani K; Koeda K; Hara H; Nakayama N; Hironaka S; Nishikawa K; Makari Y; Amagai K; Ueda S; Yoshida K; Shimodaira H; Nishina T; Tsuda M; Kurokawa Y; Tamura T; Sasaki Y; Morita S; Koizumi W
    Lancet Gastroenterol Hepatol; 2017 Apr; 2(4):277-287. PubMed ID: 28404157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.